The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With ADHD: A Lipidomic Study

• Status: Not yet recruiting
• Trial end date: 2022-07-31
• Target enrollment: 0
• Participant gender: All

Summary

1. To identify the difference in the lipidomic profiles between ADHD and controls;

2. To examine the effects of methylphenidate and atomoxetine on the lipidomic profiles in ADHD, and the relationship between medication-related changes in the lipidomic profiles and medication-related improvements in the behavioral symptoms and neuropsychological functions;

3. To map medication-related lipidomic biomolecules to their respective metabolic pathways to identify the underlying mechanisms of neuroprotective effects of methylphenidate and atomoxetine.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Atomoxetine Hydrochloride; Methylphenidate; Neuroprotective Agents

Criteria

Subjects will be recruited in the present project if they meet the following inclusion criteria:

1. Children or adolescents, between 6 and 18 years of age, must have ADHD based on the diagnostic criteria of the Diagnostic and Statistical Manual of Mental disorders, 5th edition.

2. Their scores of Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) is greater than 4 at baseline.

3. They have to be medication-naïve. They never receive any medication for the treatment of ADHD.

4. They and their parents must understand sufficiently to communicate properly with the investigators.

5. They must have a Full-Scale Intelligence Quotient (FIQ) score greater than 80.

6. They must keep regular clinic visits and all required tests, including collection of blood sample and neuropsychological testing.